HeartBeam Grants Founder Performance-Based Equity and Bonus Incentives
TipRanks' Prime Week Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
HeartBeam ( (BEAT) ) has issued an announcement.
On June 15, 2026, HeartBeam, Inc.’s compensation committee approved a performance-based restricted stock unit award for President and founder Branislav Vajdic, covering 2,800,000 units under its 2022 Equity Incentive Plan. The award vests only upon achievement of specified operational, software, product-development and clinical milestones within a defined period, alongside time-based vesting over three years, with provisions for accelerated vesting upon a change in control or qualifying termination.
On the same date, the company also entered into a transaction bonus agreement with Vajdic, tying his potential payout to meeting defined market capitalization and per-share price thresholds in connection with a qualifying change in control. Any bonus will mirror the form of consideration received by shareholders and will only be paid if those thresholds are achieved, underscoring HeartBeam’s use of performance-linked incentives to align executive rewards with shareholder value creation and strategic transaction outcomes.
The most recent analyst rating on (BEAT) stock is a Buy
with a $2.50 price target.
To see the full list of analyst forecasts on HeartBeam stock,
see the BEAT Stock Forecast page.
Spark’s Take on BEAT Stock
According to Spark, TipRanks’ AI Analyst, BEAT is a Neutral.
The score is weighed down primarily by weak financial performance (pre-revenue, sizable losses, and ongoing cash burn with a diminished equity cushion) and bearish technicals (price below key moving averages with negative MACD). These are partially offset by a more constructive earnings-call outlook, led by extended runway from the recent offering and improved cash burn guidance, but near-term revenue and execution/regulatory risks remain significant.
To see Spark’s full report on BEAT stock,
click here.
More about HeartBeam
HeartBeam, Inc. operates in the medical technology sector, focusing on cardiac care solutions. The company develops software- and device-based products aimed at improving detection and management of cardiac events, positioning itself in a niche segment of the broader healthcare and medical diagnostics market.
Average Trading Volume: 926,987
Technical Sentiment Signal: Sell
Current Market Cap: $42.16M
See more insights into BEAT stock on TipRanks’ Stock Analysis page.
